Cemiplimab, an anti-programmed cell death protein-1 (PD-1) agent, demonstrated excellent efficacy in patients with locally advanced or metastatic CSCC in a phase I/II clinical trial [15,16]. This evidence concerns the gene PDCD1 and skin squamous cell carcinoma.